Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR Government Affairs Committee’s Outgoing Chair Urges Members to Continue Advocating for Rheumatology

Mary Beth Nierengarten  |  Issue: January 2017  |  January 18, 2017

Billion Photos/shutterstock.com

Billion Photos/shutterstock.com

WASHINGTON, D.C.—Although political polarization in the U.S. has affected many people’s interest in participating in legislative and advocacy efforts that promote their concerns, William Harvey, MD, MSc, the ACR’s (immediate past) chair of the Government Affairs Committee, encouraged rheumatologists and ACR/ARHP members to remain engaged and get involved with the ACR to fight for issues that affect their practice and patients.

“It is key for continual ACR advocacy to keep the focus on issues important to physicians and patients,” he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Harvey, who is also an assistant professor in the Department of Rheumatology at Tufts University School of Medicine in Boston, spoke during the 2016 ACR/ARHP Annual Meeting at a session updating attendees on current and ongoing legislative and regulatory issues.

A cheat sheet handed out to participants provided a quick summary of the advocacy work done in 2016 by the ACR and rheumatology advocates, including having CMS agree to add more flexibility to the MACRA payment program and allow avoidance of penalties in 2017; garnering strong bipartisan opposition to the proposed Part B drug payment program; advocating for increases in research appropriations; helping increase patient access to treatment through advocacy with payers; and supporting 11 state legislative wins— among other work.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Other highlights include growing participation by rheumatologists in advocacy work, as demonstrated by more than 7,800 emails sent to Congress on policy issues, more than 250 meetings by ACR/ARHP members in congressional offices and more than 40 RheumPAC-supported fundraisers for congressional candidates.

Update on Key Issues

Among the issues that Dr. Harvey said the ACR has been fighting to prevent “tooth and nail” is the Part B Drug payment demonstration (demo) proposed by the Centers for Medicare and Medicaid Services (CMS). Saying that passage of the Part B resolution would negatively affect some of the most vulnerable patients that rheumatologists see, Dr. Harvey said the ACR is “sparing no time, energy or expense on overturning it.” [Note: Following the Annual Meeting, these efforts appeared to pay off, with no final rule released.]

Another issue that Dr. Harvey thought could gather speed now that the Republicans will hold a majority in the Congress and given promises by President-Elect Trump to increase military spending is the need to increase investment in rheumatology research. Currently, the ACR is advocating for the creation of a $20 million dedicated arthritis research program at the Department of Defense [DOD]. “Now is the perfect time to get line-item research on arthritis through the DOD,” he said.

Dr. Harvey also emphasized that the time is right to push the incoming Congress to support efforts underway to increase biomedical research funding. Currently, the ACR is supporting $34.5 billion for the NIH in the FY 2017 Labor, Health and Human Services Appropriations Bill that includes funding of the 21st Century Cures legislation and supports $13 million for the Centers for Disease Control and Prevention Arthritis Program in the FY 2017 Labor Health and Human Services (HHS) Appropriations Bill. “Our selling point to the Republican administration is that growth in NIH funding is an investment in economic growth,” he said, adding that advocacy for increased research spending is done through telling the story of how research affects patients.

He also spoke about efforts by the ACR to help patients access specialty therapies, saying that the ACR supports the bipartisan Patients’ Access to Treatment Act (PATA) bill (H.R. 1600) that limits the amount a patient is required to pay out of pocket for infusion drugs. Currently, the bill is in the House, and the ACR is trying to get members to help introduce PATA in the Senate.

Rheumatologist participation in advocacy is growing, with more than 7,800 emails sent on policy issues …

View from the Floor

Shining a political light on what rheumatologists can expect from the new administration, Rep. John Shimkus (R-Ill.) promoted free market mechanisms to manage and solve the myriad issues raised during the session.

For example, when asked by an audience member about concerns over the high and increasing price of drugs for such diseases as lupus and rheumatoid arthritis, Rep. Shimkus agreed that the price of drugs is a valid concern, but said not to expect the Republican Congress to advocate price controls. Instead, he said that he is for more competition and more products, implying that the free market is the best way to address high drug prices.

Regarding biomedical research money and a question from the audience on where Republicans stood in terms of NIH funding, Rep. Shimkus expressed strong support for the NIH, but said if even more discretionary dollars are desired, then Congress will need help with reforming mandatory spending on such programs as Social Security and Medicare.

Speaking to the overall issue of the session on advocacy efforts by the ACR to address member concerns, Rep. Shimkus emphasized that rheumatologists, health professionals and patients need to continue work to help protect their interests, practices and patients. “The Constitution allows you to collectively organize to air grievances,” he told audience members.

A View From Above

Despite the election cries from Republications to repeal the ACA, both Dr. Harvey and Rep. Shimkus speculated that some provisions in the ACA may be retained, such as not denying coverage based on preexisting conditions and allowing dependents up to 26 years of age to be covered under their parents’ or caregivers’ insurance. Parts of the ACA that they both think will be repealed will be those that are determined through budget reconciliation, including Medicaid expansion and the insurance exchanges.

Dr. Harvey emphasized that neither extreme political approach has or will help patients. “Both parties are at the extremes currently, and we [the ACR] need to move to the middle to keep the pressure on [Congress] to get our issues addressed,” he said.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:Legislation & AdvocacyMeeting Reports Tagged with:2016 ACR/ARHP Annual MeetingAdvocacyAmerican College of Rheumatology (ACR)Dr. William HarveyGovernment Affairs CommitteeLegislationrheumatologist

Related Articles

    Challenges Rheumatologists Will Face in 2017

    October 31, 2016

    Rheumatologists and rheumatology health professionals interested in knowing more about the major legislative and regulatory issues that may have an impact on their practice will want to attend the Legislative and Regulatory Update 2016 session at the upcoming ACR/ARHP Annual Meeting. On Tuesday, Nov. 15, from 7:30–8:30 a.m. in Room 140A, Will Harvey, MD, MSc,…

    State of RheumPAC: 2015 Annual Report

    May 13, 2016

    Stephen VanHorn/shutterstock.com Dear Friends and Colleagues, With your strong support and commitment, RheumPAC has grown again for the eighth straight year, allowing us to do even more on your behalf. Not only did we exceed our original goal by raising more than $150,000. More importantly, these donations came from nearly 350 ACR and ARHP members—a…

    Evolution of Medicare’s Merit-Based Incentive Payment System: MIPS Value Pathways

    December 1, 2022

    In November, the CMS finalized 12 MIPS Value Pathways (MVP) in the Quality Payment Program, including a rheumatology MVP. In 2023, clinicians can opt to report via traditional MIPS, the rheumatology MVP or both.

    MACRA: More Points, Smarter Future

    December 14, 2016

    As the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is implemented in January with new models for quality-based reimbursement payments, rheumatologists must seize control of how they will be paid now—and in the future. This message was stressed by speakers during Holy MACRA! How to Survive and Thrive in the Era of MACRA,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences